Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11306960 | 0.85 | MCHR1 (0.69) | MCHR1 | |
| SCHEMBL21928911 | 0.82 | MAPK1 (0.58) | TSHRMAPK1OPRK1MEN1KMT2A | |
| SCHEMBL10108811 | 0.82 | MAPK1 (0.58) | TSHRABCG2MAPK1OPRK1SMN1; SMN2 | |
| SCHEMBL21834930 | 0.82 | MAPK1 (0.58) | TSHRABCG2MAPK1OPRK1SMN1; SMN2 | |
| SCHEMBL21034369 | 0.80 | MAPK1 (0.56) | TSHRABCG2MAPK1OPRK1SMN1; SMN2 | |
| SCHEMBL3140700 | 0.79 | POLB (0.77) | TSHRMAPK1OPRK1MEN1KMT2A | |
| SCHEMBL21033834 | 0.79 | MAPK1 (0.55) | TSHRABCG2MAPK1OPRK1MEN1 | |
| SCHEMBL22475325 | 0.79 | MAPK1 (0.55) | TSHRABCG2MAPK1OPRK1SMN1; SMN2 | |
| SCHEMBL11395220 | 0.79 | MCHR1 (0.77) | MCHR1 | |
| SCHEMBL21834879 | 0.79 | MAPK1 (0.52) | TSHRABCG2MAPK1OPRK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | TSHR 2882/4885ABCG2 1229/4885MAPK1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.